Mathes Company Inc. cut its stake in Amgen, Inc. (NASDAQ:AMGN) by 20.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,530 shares of the medical research company’s stock after selling 1,460 shares during the period. Mathes Company Inc.’s holdings in Amgen were worth $1,031,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. PGGM Investments raised its stake in shares of Amgen by 2.3% in the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after acquiring an additional 15,059 shares during the last quarter. Shelton Capital Management raised its stake in shares of Amgen by 82.7% during the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after buying an additional 49,354 shares during the last quarter. Greylin Investment Mangement Inc. raised its stake in shares of Amgen by 466.9% during the second quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock worth $2,416,000 after buying an additional 11,555 shares during the last quarter. Kelman Lazarov Inc. raised its stake in shares of Amgen by 8.2% during the second quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock worth $272,000 after buying an additional 120 shares during the last quarter. Finally, Osborne Partners Capital Management LLC raised its stake in shares of Amgen by 0.5% during the second quarter. Osborne Partners Capital Management LLC now owns 17,023 shares of the medical research company’s stock worth $2,932,000 after buying an additional 91 shares during the last quarter. 78.46% of the stock is owned by institutional investors.
In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total transaction of $269,665.75. Following the completion of the transaction, the executive vice president now owns 56,106 shares in the company, valued at $9,921,223.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders sold 8,575 shares of company stock valued at $1,509,339 in the last quarter. Corporate insiders own 0.19% of the company’s stock.
Amgen, Inc. (AMGN) opened at $176.87 on Wednesday. The firm has a market cap of $128,390.00, a P/E ratio of 14.07, a PEG ratio of 2.57 and a beta of 1.36. Amgen, Inc. has a 1-year low of $145.12 and a 1-year high of $191.10. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business’s quarterly revenue was down .7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.02 earnings per share. sell-side analysts expect that Amgen, Inc. will post 12.66 EPS for the current fiscal year.
Amgen declared that its Board of Directors has approved a stock buyback program on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be issued a $1.32 dividend. This represents a $5.28 annualized dividend and a dividend yield of 2.99%. The ex-dividend date is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio is 41.55%.
COPYRIGHT VIOLATION NOTICE: “Amgen, Inc. (AMGN) Shares Sold by Mathes Company Inc.” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/12/20/amgen-inc-amgn-shares-sold-by-mathes-company-inc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.